Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors

被引:61
作者
Chen, Duo [1 ]
Chan, Rosemarie [1 ]
Waxman, Samuel [1 ]
Jing, Yongkui [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA
关键词
D O I
10.1158/0008-5472.CAN-06-0409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanism of apoptosis induced by treatment with As2O3 alone or in combination with buthionine sulfoximine (BSO) was studied in NB4, U937, Namalwa, and Jurkat cells. As2O3 at concentrations < 2 mu mol/L induced apoptosis in NB4 cells and Namalwa cells but not in U937 and Jurkat cells. As2O3-induced apoptosis in NB4 cells and Namalwa cells correlated with increase of H2O2 and caspase activation without activation of c-Jun NH2-terminal kinase (JNK). BSO (10 mu mol/L) depleted the reduced form of intracellular glutathione without inducing apoptosis but synergized with 1 mu mol/L As2O3 to induce apoptosis in all four cell lines. This synergy correlated with JNK activation. Treatment with As2O3 plus BSO, but not with As2O3 alone, increased the levels of death receptor (DR) 5 protein and caspase-8 cleavage. The JNK inhibitor SP600125 inhibited the increase in DR5 protein and attenuated apoptosis induced by treatment with As2O3 plus BSO. These observations suggest that a DR-mediated pathway activated by JNK is involved in apoptosis induced by treatment with As2O3 plus BSO.
引用
收藏
页码:11416 / 11423
页数:8
相关论文
共 43 条
[1]   Arsenic-induced apoptosis in malignant cells in vitro [J].
Akao, Y ;
Yamada, H ;
Nakagawa, Y .
LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) :53-+
[2]   The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines -: With a comparison of its effects on other cell lineages [J].
Alemany, M ;
Levin, J .
LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) :153-+
[3]   Arsenic trioxide: Acute promyelocytic leukemia and beyond [J].
Bachleitner-Hofmann, T ;
Kees, M ;
Gisslinger, H .
LEUKEMIA & LYMPHOMA, 2002, 43 (08) :1535-1540
[4]   Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? [J].
Bachleitner-Hofmann, T ;
Gisslinger, B ;
Grumbeck, E ;
Gisslinger, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :783-786
[5]  
Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658
[6]   Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells [J].
Bazarbachi, A ;
El-Sabban, ME ;
Nasr, R ;
Quignon, F ;
Awaraji, C ;
Kersual, J ;
Dianoux, L ;
Zermati, Y ;
Haidar, JH ;
Hermine, O ;
de Thé, H .
BLOOD, 1999, 93 (01) :278-283
[7]   A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma [J].
Berenson, JR ;
Swift, RA ;
Ferretti, D ;
Purner, MB .
CLINICAL LYMPHOMA, 2004, 5 (02) :130-134
[8]   Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma [J].
Borad, MJ ;
Swift, R ;
Berenson, JR .
LEUKEMIA, 2005, 19 (01) :154-156
[9]  
Chen GQ, 1997, BLOOD, V89, P3345
[10]  
Chen GQ, 1996, BLOOD, V88, P1052